Preclinical stage biopharmaceutical company with strong IP in the field of targeting mutant calreticulin (CALR).
R&D:Exploring novel targets and therapeutics for unmet medical need in the area of rare leukemia and myeloproliferative neoplasms.
Lazarettgasse 14, BT 25.3, CeMM Building, Level 3
1090 Vienna
Vienna
Contact:
Telephone: +43 (664) 882-62093
Email: office@myelopro.com
Website